- One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment2023 | First Faculty of Medicine
- Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network2023 | First Faculty of Medicine
- Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD2023 | First Faculty of Medicine, Faculty of Science, Second Faculty of Medicine
- Long-term outcomes of ixekizumab treatment in patients with axial spondyloarthritis2023 | First Faculty of Medicine
- Janus kinase inhibitors in clinical practice: data from the ATTRA registry2020 | First Faculty of Medicine
- Tocilizumab in the treatment of juvenile idiopathic arthritis2019 | Publication without faculty affiliation
- Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching2023 | First Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine